/This news release is intended for distribution in Canada It is intended for distribution only and is not intended for distribution. America newswire service or distribution in US./
vancouver british columbia, February 16, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus) (TSX: NUMI) is a mental health care company advancing traditional and innovative behavioral health therapies with a focus on safe, evidence-based psychedelic-assisted therapies, and is currently engaged in a previously announced acquisition transaction. announced the completion of its initial public offering. 50,000,000 units (each “unit“) at the price of $0.12 per unit (“Offering price“) Total revenue against Numinus 6 million dollars (“”Recruitment“).
Each Unit consists of one common share in the capital stock of Numinus (each “common stock“) and one Numinus common stock purchase warrant (each, “warrantEach stock acquisition right is exercisable to obtain one common share at the exercise price during a period of 24 months from the closing of the offering. $0.18 per common share.
“Numinus is at a critical stage. With the recent acceptance of a new drug application for MDMA by the U.S. Food and Drug Administration, our clinical research team continues to work on exciting new drugs and treatments, and our training platform “We are contributing to addressing this issue. There is a critical need for practitioners to offer psychedelic-assisted therapy.” Peyton Nykvest, Founder and CEO of Numinus. “This funding provides us with the resources to act on opportunities and shows support for our work in the market. This, along with Drs. rick doblinFounder and President of the Interdisciplinary Association for Psychedelic Research, joins us as an unpaid, non-exclusive strategic advisor, strengthening our efforts to provide much-needed transformative care it was done. ”
Dr. rick doblin “Numinus is making significant advances in the mental health field through its strategic focus and thoughtful positioning. Their approach, particularly through proposed clinical trials for experiential training, effectively supports It is well designed to provide therapists with the deep understanding needed to help people cope with trauma. ”
Dane StevensCo-founder of Optimi Health Corporation and Health Canada dealer license holder, he is committed to participating in this recruitment and supporting Numinus’ future efforts. “We are proud to support Numinus’ strategic efforts to ultimately expand access to healthcare.” Psychedelic-assisted therapy. Supporting industry-leading clinic efforts and training efforts is an important step in ensuring access. ”
Numinus intends to use the proceeds from the initial public offering for working capital and general corporate purposes.
This unit was sold pursuant to an underwriting agreement dated. February 5, 2024 (“”underwriting agreement“) Numinus, Eight Capital, Stifel Nicolaus Canada Inc., and Haywood Securities Inc. (collectively “underwriter“).
Pursuant to the underwriting agreement, Numinus provides the underwriter with an option (“Over-allotment options“) Exercisable at any time within 30 days after the offering closes, you may purchase up to 15% additional units at the offering price per unit, resulting in up to $20 in additional proceeds. $900,000 If the overallotment option is exercised in full. The overallotment option may be exercised to acquire stock acquisition rights, common stock and/or stock acquisition rights (or a combination thereof) at the discretion of the underwriters.
This offering was completed pursuant to a prospectus supplement dated: February 5, 2024 (“”supplement“) Numinus short form basic shelf prospectus date June 27, 2023 (“”prospectus“), in all states Canadaoutside of Quebec, and in US Pursuant to Rule 144A of the Securities Act of 1933, as amended, transfers to “qualified institutional buyers” (“US securities laws“) and also in other jurisdictions outside Canada and US Subject to an exemption from prospectus and registration requirements.
Certain directors and officers of Numinus (collectively, “”)insider“) purchased a total of 1,708,333 units pursuant to the offering. Insider participation in the offering was deemed a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of minority security holders in special transactions (“MI 61-101Numinus is exempt from the requirement to obtain formal evaluation or minority shareholder approval in connection with insider participation in public offerings under sections 5.5(a) and 5.7(1)(a) of MI 61-101. I did. The fair market value of securities issued to insiders, or the consideration paid by insiders, exceeded 25% of Numinus’ market capitalization. Numinus did not file a material change report 21 days prior to the closing of the offering due to the lack of insider participation. At that time, the transaction had been confirmed and Numinus wanted to complete the transaction as soon as possible for sound business reasons.
The securities being offered pursuant to the offering have not been and will not be registered under the U.S. Securities Act or the securities laws of any U.S. state and may not be offered or sold on any U.S. securities exchange. US or for or for the benefit of America Any person who has not registered or has not exercised an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people heal and stay healthy through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. We support. The Numinus model, which includes psychedelic research and clinic care, is at the forefront of a transformation aimed at healing rather than managing symptoms such as depression, anxiety, trauma, pain, and drug use. At Numinus, we are leading the way in integrating psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more about www.numinus.com and follow us linkedin, Facebook, twitterand Instagram.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, projections, projections, objectives, assumptions, expectations, or beliefs regarding future performance, are “forward-looking” statements. “description regarding”. Forward-looking statements include “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, It can be identified by the use of words such as “I believe.” or variations of these words, expressions, or statements, such as “may,” “could,” “will,” “likely,” or “a particular action, event, or result” “will be done,” something that will happen, or come to pass. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that may cause actual results, events or developments to differ from those anticipated, expressed or implied in such forward-looking statements. Actual results, events and developments could differ materially. These risks and uncertainties include, but are not limited to, restrictions imposed on his use of MDMA by regulatory authorities; Safety and efficacy of MDMA-assisted therapy. Acceptance, dissemination, and commercialization of MDMA-assisted therapy. the effectiveness of advice provided by or future collaborations related to the Strategic Advisor; management’s ability and/or effectiveness in deploying the proceeds of the offering as planned; Numinus’ ability to maintain or increase its revenues; Numinus’ ability to achieve or maintain profitability; Numinus’ need for additional financing and the effect of financial market conditions and other factors on the availability of capital;and other risk factors described in the supplement, prospectus and annual information form dated. November 29, 2023, each available on SEDAR+ at www.sedarplus.ca. These factors should be considered carefully and readers are cautioned not to place undue reliance on forward-looking statements. Although Numinus has attempted to identify key risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there are other risk factors. may cause actions, events or developments to differ materially from those anticipated, estimated or predicted. It was intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results or future events could differ materially from those anticipated in the forward-looking statements. Numinus reserves the right to revise any forward-looking statements, whether as a result of future events, new facts or for any other reason, if new information becomes available, except as required by applicable law. We do not promise
Source Numinus Wellness Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/16/c5247.html
